222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000185-42-FR (EUCTR) | 12/06/2020 | 26/05/2020 | Phase 2a Study of VX 147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. | A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. | APOL1-mediated Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Product Name: VX-147 Product Code: VX-147 INN or Proposed INN: VX147 Other descriptive name: VX-147 | Vertex Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | United States;France;United Kingdom | ||
| 2 | NCT04340362 (ClinicalTrials.gov) | June 8, 2020 | 7/4/2020 | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | Glomerulosclerosis, Focal Segmental | Drug: VX-147 | Vertex Pharmaceuticals Incorporated | NULL | Completed | 18 Years | 65 Years | All | 16 | Phase 2 | United States;France;Puerto Rico;United Kingdom |
| 3 | EUCTR2020-000185-42-GB (EUCTR) | 01/06/2020 | 23/03/2020 | Phase 2a Study of VX 147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. | A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis. | APOL1-mediated Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Product Name: VX-147 Product Code: VX-147 INN or Proposed INN: VX147 Other descriptive name: VX-147 | Vertex Pharmaceuticals Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 2 | France;United States;United Kingdom |